By February 2016 all major I3 access programs at the PSI user facilities SLS, SINQ and SμS within the EC Framework Programme 7 came to an end. Those were programs like CALIPSO, Biostruct-X or NMI3. Presently we do have the following information about successor programs and the future of user support by the EC:
SINQ and SμS:
SLS and SwissFEL:
The proposal for a new I3 access program (CALIPSOplus) under the framework program HORIZON2020 has been accepted for funding by the EC. Funding is secured since May 2017. The SLS with all its beamlines and also SwissFEL fully participate in the program, which means that part of the users can financially be supported again. Further detailed information is available here.
One part of these programmes is to provide access to users from EC countries and associated states (except Switzerland) and to support those user visits by travel and subsistence funds. The guidelines for funding might differ between the facilities and depend on the available budget.
For detailed information about the funding options at the three facilities and the necessary procedures and formalities please visit the programme-specific sites listed in the navigation menu on the left.
Coverage of funding
Criteria for eligibility
Please note that not each eligible proposal can be funded due to limited amount of available funds. If an experiment is eligible and has passed the criteria for funding we usually reimburse the expenses for one member of a group of scientists performing an experiment at our facilities. The group leader of the experimental team is free to decide which scientist out of his team should be supported but it has to be somebody affiliated to one of the countries listed below.
An experiment is eligible for funding if...
- both the user group leader (main proposer) and the majority of the users are affiliated to institutions from EU member states or associated states, see table below.
- both the user group leader and the majority of the users are affiliated to institutions outside of Switzerland.
Criteria for funding
|EU member countries (EU-27)|
|Austria (AT)||Belgium (BE)||Bulgaria (BG)||Croatia (HR)|
|Cyprus (CY)||Czech Republic (CZ)||Denmark (DK)||Estonia (EE)|
|Finland (FI)||France (FR)||Germany (DE)||Greece (GR)|
|Hungary (HU)||Ireland (IE)||Italy (IT)||Latvia (LV)|
|Lithuania (LT)||Luxembourg (LU)||Malta (MT)||Netherlands (NL)|
|Poland (PL)||Portugal (PT)||Romania (RO)||Slovakia (SK)|
|Slovenia (SI)||Spain (ES)||Sweden (SE)|
|Albania (AL)||Armenia (AM)||Bosnia & Herzegovina (BA)||Faroe Islands (FO)|
|Georgia (GE)||FYR Macedonia (MK)||Iceland (IS)||Israel (IL)|
|Moldova (MD)||Montenegro (ME)||Norway (NO)||Serbia (RS)|
|Turkey (TR)||Tunisia (TN)||United Kingdom (UK)||Ukraine (UA)|
Please note: Switzerland is an EC associated country to Horizon 2020 but is not eligible for transnational access funding to Swiss research facilities. Unlike in FP7, Liechtenstein does not intend to associate to Horizon 2020, more information.